By Godson Umejiego, Senior Correspondent, USA

Komodo Health, a technology company driving patient-centric insights at scale, and Datavant, the leader in helping organizations securely connect health data, today announced an expansion of their partnership. Together, they will enable life sciences companies to securely connect proprietary and third-party clinical trial data, specialty pharmacy data, and more to Komodo’s technology and insights platform, driving more value than ever before from their data.

Real-world evidence (RWE) is increasingly crucial for decision-making within the Life Sciences industry, offering insight into how patients navigate the healthcare system. However, disconnected, siloed data that cannot interoperate leaves an incomplete view of the patient journey. The partnership between Komodo and Datavant enables patient data to be de-identified, and linked across datasets without compromising patient privacy. By connecting their internal data to Komodo’s Healthcare Map of real-world data, companies can gain critical insights to accelerate innovation, generate evidence, and measure their commercial effectiveness.

“As one of Datavant’s first partners, we are thrilled to be on a journey with them to democratize access to clinical insights at scale,” noted  co-founder and CEO of Komodo Health, Arif Nathoo, MD. “Using Datavant’s technology, Komodo’s platform has been supporting clinical development teams to unlock the value of real-world evidence to increase health equity in site selection, improve speed of recruitment and support research to reduce the burden of disease.”

The Datavant and Komodo partnership enables companies to link de-identified, proprietary data to Komodo’s Healthcare Map, which includes claims, electronic health records, diagnostic tests, and demographic data. These linkages can address a wide range of healthcare and life science pain points, such as:

Clinical Development: Connecting clinical trial data with real-world data can lead to richer insights before, during, and after the trial, and more effectively support long-term safety and effectiveness measurement.

Patient Finding: Linking external data with the Healthcare Map allows researchers to create a “true positive” set of de-identified patients that can be used to train a predictive model or identify other, similar patients.

Disease Prevalence and Burden: Pairing customer and other third-party data with Komodo’s longitudinal view of encounters with the healthcare system for over 330 million US patients provides powerful evidence to support epidemiology and health outcomes research.

Commercial Intelligence: Combining lab and diagnostic data with Komodo’s Healthcare Map unlocks insights that can help segment patients based upon diagnostic results, conduct detailed patient journey analyses by segment, and use those insights to shape and measure commercial activities.

Deeper insights into the journeys of trial participants strengthens longitudinal research studies, helping companies to define and improve sub-group analysis, and provide insight into patient treatment response and long-term safety and effectiveness based on a myriad of factors only captured through RWD.

“We’re excited for this next phase of our partnership with Komodo,” said Founder and President of Datavant, Travis May,. “As a leading health technology platform, Komodo has validated the utility of connected health data as they solve critical healthcare challenges across payers, providers, and biopharmaceutical companies. We are thrilled to enable the linkages that can help change the paradigm for how clinical trials are run, supporting the seamless incorporation of real-world data to answer a variety of challenging research questions.”

On April 12, Komodo and Datavant will host a webinar for clinical development and RWE teams to learn more about the value of linking real-world data to clinical trials, without unblinding the study or compromising privacy. Register for the webinar here.